Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact

C. M. Prado1*, S. J. Cushen2, C. E. Orsso1 and A. M. Ryan2

1Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada
2School of Food and Nutritional Sciences, University College Cork, Cork, Republic of Ireland

Our understanding of body composition (BC) variability in contemporary populations has significantly increased with the use of imaging techniques. Abnormal BC such as sarcopenia (low muscle mass) and obesity (excess adipose tissue) are predictors of poorer prognosis in a variety of conditions or clinical situations. As a catabolic illness, a defining feature of cancer is muscle loss. Although the conceptual model of wasting in cancer is typically conceived as involuntary weight loss leading to low body weight, recent studies have shown that both sarcopenia and cachexia can be present with obesity. The combination of low muscle and high adipose tissue (sarcopenic obesity) is an emerging abnormal BC phenotype prevalent across the body weight, and hence BMI spectra. Sarcopenia and sarcopenic obesity in cancer are in most instances occult conditions, which have been independently associated with higher incidence of chemotherapy toxicity, shorter time to tumour progression, poorer outcomes of surgery, physical impairment and shorter survival. Although the mechanisms are yet to be fully understood, the associations with poorer clinical outcomes emphasise the value of nutritional assessment as well as the need to develop appropriate interventions to countermeasure abnormal BC. Sarcopenia and sarcopenic obesity create diverse nutritional requirements, highlighting the compelling need for a more comprehensive and differentiated understanding of energy and protein requirements in this heterogeneous population.

Body composition (BC) is a science that explores nutritional status in view of the different contributions of lean v. adipose tissue and its impact on health. The fast growing evidence of the importance of BC assessment may be attributed to the development of new in vivo technology and the resulting identification of abnormal BC phenotypes that can, in turn, negatively impact prognosis in any population. Here, we will briefly discuss recent advances in BC assessment, focusing on the prevalence and significance of these abnormal phenotypes in patients with cancer. Additionally, we will contextualise abnormal BC in view of the need for targeted nutrition interventions. Although the focus of this paper is oncology patients, we argue that issues hereby discussed are broadly relevant to other populations that, like cancer, have chronic diseases characterised by older age and inflammation and where concurrently obesity also occurs. These include, but are not limited to chronic obstructive pulmonary disease, insulin resistance/type II diabetes, cirrhosis, rheumatoid arthritis and congestive heart failure.

Variability in body composition: a new face of an old problem

When one is asked to imagine how abnormal BC looks like in cancer, the idea of a cachectic looking, extremely...
emaciated person would likely be conceived by most people. As a public person, Steve Jobs’ weight loss towards the end of his cancer disease trajectory was a classic example of how terminal illness is pictured. Weight loss (and muscle loss) is an important component of cancer, particularly advanced cancer and is observed as part of the conceptual model of cancer progression. This trajectory is characterised by involuntary weight loss that increases exponentially in incurable cancers with a notable acceleration in the last few months prior to death \[^8\], a process also known as cancer cachexia.

Cancer cachexia can nonetheless manifest without the concurrent phenotype of emaciation. Medical oncologists nowadays face a new issue as 40–60 % of their patients present with excess body weight (overweight and obesity) at the time of cancer diagnosis \[^9\]. Nonetheless, obesity does not preclude the presence of cancer cachexia and can indeed mask its appearance \[^10,11\], a concept that has been changing paradigms in oncology research and practice. This new face of an old problem was first identified with the use of BC analysis, which looks beyond body weight and BMI and quantifies the different proportions of lean vs. adipose tissue within a unit of body weight \[^11\].

### Computerised tomography: an opportunistic tool

Our understanding of BC research in cancer has substantially advanced due to the use of computerised tomography (CT) imaging scans. These images are readily available from electronic libraries of medical images taken for cancer diagnosis and prognostic follow up \[^12\]. CT images can be retrieved for the additional purpose of BC analysis providing accurate and reliable information on muscle and different adipose tissue depots at the third lumbar vertebra cross-sectional area (Fig. 1), an area chosen as the best correlate to whole BC \[^13\]. Using image specific analysis software (free-of-charge and paid): SliceOMatic, Tomovision; MeVislab, MeVis Medical Solutions AG; UltraVisual, UltraVisual Medical Systems Inc; ImageJ, National Institutes of Health; OsiriX, Pixmeo; analyzer Synapse Vincent 3D image analysis system, Fujifilm Medical, among others, tissue marking and automated computation can be accomplished. In addition to the availability of the image and the software for its analysis, trained personnel are also essential for accurate and reliable evaluation (note a radiologist is not required). These methods are highly reproducible, and have minimal additional cost. Importantly, automated software is currently being developed for rapid and practical imaging analysis \[^14\].

Two brief videos containing an overview of the third lumbar vertebra CT analysis for BC using two different software are available at our UofANutrition YouTube channel: https://www.youtube.com/watch?v=s1eJSK_CWco and https://www.youtube.com/watch?v=KJrsQ_dg5mM

The procedures for image analysis include finding the landmark of interest (third lumbar vertebra) and retrieving it for analysis (Digital Imaging and Communications in Medicine, DICOM format) by utilising the software of choice or a specific browser (e.g. iQ-VIEW, PACS, which are free DICOM viewers). Next, the image is uploaded in the software of choice for tissue analysis, where muscle and adipose tissue can be evaluated based on differences in pre-established measures of Hounsfield unit attenuations as follows: −29 to +150 for skeletal muscle \[^15\], −190 to −30 for subcutaneous and intermuscular adipose tissue \[^15\] and −150 to −50 for visceral adipose tissue \[^15\].

### Defining divergent behaviour of muscle and adipose tissue in cancer

Using CT image analysis we, and others, were able to identify a great variability of BC in contemporary cancer patients \[^10,17-20\]. Fig. 2. As illustrated in this figure, patients with any given BMI can present with severe muscle depletion (sarcopenia) or with normal muscle mass. Alternatively, individuals may present with BMI of different (and extreme) categories, yet have exactly the same amount of muscle mass, Fig. 3.

As a catabolic illness, a defining feature of cancer is muscle loss. Low muscle mass, also termed sarcopenia is common in people with cancer regardless of stage (i.e. from curative to palliative). In fact, the overall prevalence of sarcopenia in the studies hereby reviewed is about 40–50 % in people with newly diagnosed cancer, considerably higher than about 15 % prevalence in healthy individuals of similar age (median 65 years) \[^21\]. Since only about 10 % of cancer patients are clinically underweight \[^20\], this widespread phenomenon of muscle depletion is independent of body weight or fat mass. Fig. 4 illustrates the widespread distribution of sarcopenia across the BMI spectrum using population cohort data of patients with colorectal cancer treated at a regional cancer centre in Alberta, Canada. Sarcopenia increased at all lower BMI strata, but was also substantially present at higher BMI. As discussed previously, sarcopenia can coexist with obesity (sarcopenic obesity), compounding health consequences for physical function and survival in cancer \[^11,23\].

Sarcopenia is different from cancer-associated cachexia. In cancer cachexia diagnoses, sarcopenia needs to
be defined in conjunction with weight loss\textsuperscript{(23)}. The understanding of abnormal BC in cancer has also impacted the definition of cancer cachexia. The international consensus group definition now recognises cancer cachexia as a:

‘Multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment’ (emphasis added)\textsuperscript{(23)}.

Therefore, sarcopenia, sarcopenic obesity and cancer cachexia can manifest at any given BMI and body weight, which may be undetected by use of these anthropometric tools alone, hence the importance of additional assessment using BC techniques. The most commonly used cutpoints to define sarcopenia have been developed in obese patients with lung or gastrointestinal cancer using optimal stratification analysis. The gender-specific values below which patients are categorised as sarcopenic are 52.4 cm\(^2\)/m\(^2\) for men and 38.5 cm\(^2\)/m\(^2\) for women\textsuperscript{(16)}. These cutpoints have been used in many different cohorts of patients and clinical populations, consistently demonstrating an association with patient prognostication\textsuperscript{(2,4,24)}. In the optimal stratification analysis approach, patients are stratified from least to most muscular and a gender-specific threshold for increased risk of a clinical outcome (in this case
Sarcopenia and Cachexia in the era of obesity

Fig. 3. (Colour online) Illustration of three male patients of different BMI presenting with similar amount of muscle cross-sectional area (skeletal muscle index = about 42.4 cm²/m²).

Implications of abnormal body composition

Despite the variability of available BC assessment tools and cutpoints, sarcopenia and sarcopenic obesity have been consistently associated as predictors of unfavourable outcomes in oncology patients. Selected examples will be discussed in this section.

Treatment toxicity

One of the very first research questions regarding the potential impact of abnormal BC on cancer prognosis was related to the issue of individualising chemotherapy treatment(30). Most chemotherapy drugs are administered based on body surface area, which is a calculation that only accounts for height and weight. Therefore, individuals with identical height, weight and hence body surface area (as presented in each BMI category in Fig. 2) would consequently be receiving exactly the same amount of chemotherapy drug(31). Such practice ignores the large individual variability in muscle mass and hence lean tissue compartment, where pharmacokinetics (drug metabolism) occurs(32–35). This concept has been extensively reviewed previously and we refer the reader to other articles for a more detailed discussion(31,32).

Based on this concept, the original hypothesis was that a sarcopenic person would receive a large amount of drug for a small lean tissue compartment; increasing this person’s risk for developing dose limiting toxicity (DLT)(31). DLT is an unfavourable and undesirable outcome of chemotherapy, which leads to treatment termination, discontinuation, hospitalisation or death. The original hypothesis was investigated using several different studies with different chemotherapy drugs and in individuals with different cancer types(31,36). In a recently published paper by Anandavadielvan et al.(26) DLT was investigated in seventy-two patients receiving neo-adjuvant therapy for oesophageal cancer. Unfortunately, absolute values of muscle mass were not stratified by gender when comparing those presenting v. not presenting with DLT. Nonetheless, using a gender-specific definition of sarcopenia, they showed that sarcopenic obese presented with higher DLT compared with their non-sarcopenic obese counterparts (OR 5.54; 95% CI 1.12, 27.44).

Collectively, these studies show that sarcopenia (without concurrent obesity) is an independent predictor of severe toxicity, affecting cancer treatment and its outcomes. The same hypothesis holds true for studies on targeted chemotherapy agents(19,37) (Fig. 5) and for hydrophobic agents, where both muscle and adipose tissue may play a role in predicting toxicity(34).

Therefore, there is enough evidence to suggest these patients behave as if they were overdosed. Future dose-escalating studies personalised by BC will illustrate the value of personalising chemotherapy treatment(38) using BC, and the respective impact on decreasing the risk of DLT consequently increasing the number of planned chemotherapy cycles in sarcopenic patients.

In addition to cancer being a catabolic condition leading to muscle loss, cancer-treatment itself can impact BC. Chemotherapy treatment can decrease muscle mass by 4.6 cm³(29) which is about 0.8 kg at the whole body
level using the regression equation in Shen et al.\(^{(13)}\):

\[
\text{whole body muscle mass} = 0.166 \times (\text{CT measured skeletal muscle (cm}^2) + 2.142, \text{ but using only the slope since the line has a non-zero intercept.}
\]

We have pioneered the findings of sarcopenic-obesity as an independent predictor of physical impairment (47 vs. 26\% in non-sarcopenic obese, \(P = 0.005\)) and survival.

---

**Fig. 4.** (Colour online) Prevalence of sarcopenia (dots) in patients with stages I–IV colorectal cancer, \(n = 684\). Consecutive patients referred to a medical oncology service in a regional cancer centre in Alberta, Canada. Considering BMI categories, sarcopenia was prevalent in 74\% of underweight patients, 42\% of normal weight, 39\% overweight, 24.4\% obese (all classes). Among the obese individuals, sarcopenia was present in 28.8\% of class I, 18.2\% class II and 14.3\% of class III obese patients. Sarcopenia defined using BMI-specific cutpoints\(^{(20)}\). Data courtesy of Dr Vickie Baracos, University of Alberta.

**Fig. 5.** (Colour online) Summary of individual study studies relating sarcopenia with dose-limiting toxicity; several antineoplastic therapies and cancer types represented. 5FU (5-fluorouracil), colorectal cancer\(^{(30)}\); Capecitabine, breast cancer\(^{(42)}\); Adjuvant FEC (%-fluorouracil, epirubicin, cyclophosphamide), breast cancer\(^{(30)}\); Sorafenib, renal cell cancer\(^{(37)}\); Sorafenib, renal cell cancer\(^{(27)}\); Sunitinib, renal cell cancer\(^{(78)}\); Vandetabin, advanced medullary thyroid carcinoma\(^{(79)}\); Fluoropyrimidine, colorectal cancer\(^{(80)}\); Imatinib, gastrointestinal stromal tumour (anaemia and fatigue)\(^{(81)}\); ECX and CF (Epirubicin, Cisplatin, Capecitabine) and CF (Cisplatin and 5-Fluorouracil), oesophagogastric cancer\(^{(82)}\).
in a population cohort of patients with lung or gastrointestinal cancer. Survival was shorter for sarcomeric obese patients compared with non-sarcopenic obese (hazard ratio (HR) 4.2; 95% CI 2.4–7.2)\(^\text{[10]}\). We have also reported similar findings in sarcomeric patients with hepatocellular carcinoma\(^\text{[46]}\), and lung or colorectal cancer\(^\text{[41]}\) and that sarcopenia is an independent predictor of shorter time to tumour progression\(^\text{[42]}\).

More recently, 2-year overall survival was lower in sarcomeric patients with diffuse large B-cell lymphoma, compared with the non-sarcopenic counterparts (46 v. 84 %, respectively) with a HR 3.22; 95% CI 1.73–5.98\(^\text{[43]}\). Miyamoto et al.\(^\text{[44]}\) investigated the prognostic effect of sarcopenia in patients with stages I–III colorectal cancer undergoing curative resection surgery. Sarcopenia was an independent predictor of shorter recurrence-free survival (HR 2.18; 95% CI 1.20–3.94) and overall survival (HR 2.27; 95% CI 1.15–4.5). In a separate study, the authors also showed that muscle mass was similarly associated with poor prognosis in patients with unresectable colorectal cancer\(^\text{[45]}\). Muscle loss >5% after chemotherapy treatment was associated with shorter overall survival (HR 2.08; 95% CI 1.19, 3–62). Sarcopenia was also a significant predictor of overall survival in patients with urothelial cancer (HR 3.36; 95% CI 1.9–6.1)\(^\text{[46]}\), hepatocellular carcinoma (HR 3.26; 95% CI 1.28–8.0)\(^\text{[47]}\) and metastatic renal cell carcinoma (HR 2.13; 95% CI 1.15–3.92)\(^\text{[48]}\). Additionally, several other recent studies have investigated the prognostic impact of sarcopenia on survival on cancer\(^\text{[39,49–51]}\), the growing body of literature on the topic is impressive.

**Broader implications**

Much broader implications can be attributed to abnormalities in BC. Sarcopenia has been associated with the development of postoperative infections, the need for in-patient rehabilitative care, incidence of hospitalisation and length of hospital stay as shown in Lieffers et al.\(^\text{[17]}\) and Peng et al.\(^\text{[52]}\). More recently, Ida et al.\(^\text{[53]}\) reported a higher incidence of postoperative respiratory complications among sarcomeric patients compared with non-sarcopenic (15.5 v. 6.5%, respectively, \(P = 0.01\)) and showed sarcopenia (OR 5.82; \(P = 0.0001\)) was a risk factor for the occurrence of respiratory complications in patients with oesophageal cancer. In patients following pancreatectomy, sarcopenia was an independent predictor of major grade III complications, length of stay, intensive care unit admission, delayed gastric emptying, and infectious, gastrointestinal, pulmonary and cardiac complications\(^\text{[54]}\). Similar results were reported by van Vugt et al.\(^\text{[55]}\) who demonstrated that sarcopenia was associated with severe postoperative complications in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal cancer.

Cancer therapy can also lead to abnormal BC. As an example, patients undergoing breast cancer therapy and androgen deprivation therapy for prostate cancer develop a pattern of fat gain with concurrent loss of lean mass (i.e. sarcomeric obesity)\(^\text{[56]}\). These patterns of change have been linked to decreased quality of life, decreased disease-free survival, increased risk of CVD, increased risk of insulin resistance/diabetes, reduced bone mass, increased risk of fractures at multiple sites and also, metabolic imbalances, consequences likely related to both sarcopenia and obesity\(^\text{[36–38]}\). Additionally, some drugs commonly used can also promote muscle loss such as corticosteroids, statins and tyrosine kinase inhibitors, as reviewed previously\(^\text{[36]}\).

**Impact of muscle radiodensity**

Another metric associated with key health outcomes is muscle radiodensity. Prado et al. were the first to report an association between low muscle attenuation and sarcopenia in cancer patients. Reduced muscle attenuation is reflective of intermuscular adipose tissue or poor ‘quality’ skeletal muscle. Aubrey et al.\(^\text{[59]}\) introduced a radiation attenuation map of paraspinal/psoas muscles depicting the myoesteatosis phenomenon, a concept illustrated in Fig. 6. This concept highlights that skeletal muscle may contain areas of normal and reduced attenuation; and that these reduced attenuation areas are within radiodensity ranges of adipose tissue. Therefore the ‘quality’ of the muscle may be affected with individuals having less than half of muscle falling within normal muscle attenuation areas. Importantly, low muscle radiodensity is emerging as an important and in some cases stronger predictor of clinical outcomes (compared with muscle mass alone). In Sabel et al.\(^\text{[60]}\) low (psoas) muscle radiodensity was associated with disease-free and distant disease-free survival (\(P = 0.04\) and \(P = 0.0002\), respectively). These results were supported by a Martin et al.\(^\text{[60]}\) study, where low muscle attenuation was a powerful predictor of survival (HR 1.36, 95% CI 1.2–1.6), and more recently by Okumura et al.\(^\text{[50]}\), who showed low muscle quality associated with poor overall (HR 2.5, \(P < 0.001\)) and recurrence free (HR 1.6; \(P = 0.004\)) survival.

**The impact of abnormal body composition on nutritional therapy**

All of the implications of sarcopenia and sarcopenic-obesity in cancer can be conceived as the potential clinical benefits of reversing these abnormalities by nutritional therapy. We now know cancer patients have anabolic potential\(^\text{[61]}\). Contrary to popular belief, sarcopenia in cancer is reversible even in people of older age, deconditioning, inflammation and concurrent comorbid conditions\(^\text{[62]}\). Evidence also shows that anabolic responsiveness is not suppressed by nutrition interventions\(^\text{[63–68]}\). In spite of this evidence, recent pharmacological studies on retention or gain of muscle mass in cancer have failed to provide (or account for) sufficient energy and protein to sustain muscle mass accretion\(^\text{[63,65]}\). While the importance of adequate nutrient intake is obvious, an important unanswered question relates to the optimal energy and protein intakes during cancer disease trajectory.
Muscle loss in cancer is partially driven by increased muscle protein catabolism, when substrate availability (protein intake) is insufficient. Not only is a supply of protein essential, but an adequate dose and balance of calories and essential nutrients are required to support maintenance or gain of muscle. The optimal amounts of protein and calories are undefined for preventing or treating sarcopenia in people with cancer. Protein intake...
by cancer patients is variable (0.2–2.7 g/kg)\(^{(69)}\) and many do not meet current dietary guidelines of 0.8 g/kg for healthy individuals\(^{(70)}\) or 1.0–1.5 g/kg for those with cancer\(^{(71–73)}\). We previously reported that 35 % of cancer patients had protein intakes below 1.0 g/kg\(^{(74)}\) and that protein intake correlated with muscle mass \((r = 0.4; P = 0.001)\) and lean mass \((r = 0.4; P = 0.003)\)\(^{(75)}\).

Current protein and energy guidelines in cancer, and across a broad spectrum of other chronic conditions, recommend daily ranges of intake adjusted by body weight. This ignores the large variability of BC in contemporary population extensively discussed earlier and also shown in Fig. 7(a). As a theoretical example, patients who weigh the same and are provided protein at 0.8 g/kg body weight would receive anywhere between 0.8 and 2.1 g protein/kg lean mass, owing to differences in BC, Fig. 7(b). The proposition that lean mass drives protein requirements is widely accepted; thus adjusting dietary targets by BC is more appropriate. The same logic can be applied to energy recommendations, which estimate targets by BC is more appropriate. The same logic can be applied to energy recommendations, which estimate

Current nutrition recommendations are inconsistent with findings of variable BC and do not meet the physiological needs of most cancer patients. At one end of the spectrum, underweight patients have elevated protein requirements due to their illness. They may receive adequate energy but inadequate amounts or quality of protein, placing them at risk for protein malnutrition and sarcopenia. In contrast, obese patients may have secondary pathologies related to their excess fat mass. They require tailored amounts and types of energy, targeted to prevent increases in fat mass and worsening of problems such as insulin resistance and lipid control. The obese patient may also have sarcopenia (sarcopenic obese), which would increase their protein needs. Thus, dietary prescriptions for energy and protein need to be disconnected. Their energy needs must relate to their obesity and other comorbidities, with protein intake targeted to protect muscle mass\(^{(11)}\).

**Conclusion**

BC is variable within patients with identical body size. Sarcopenia and sarcopenic obesity are prevalent, can occur concurrently with cachexia and are prognostic for poorer quality of life, longer length of hospital stay, rehabilitation care, postoperative complication, survival, among others. Given the high and increasing prevalence of cancer and the high incidence of sarcopenia in people with cancer, sarcopenia and its attendant health risks and functional deficits are a significant problem potentially affecting hundreds of thousands of cancer patients.

The variability in BC in contemporary cancer population creates diverse nutritional requirements which have nonetheless been established as a range of intake, with no specific target for patients to achieve. Assuming that protein and energy feeding may be done by body weight ignores this variability in BC, promoting or enhancing the sarcopenic or sarcopenic obesity phenotype. Dietary guidelines for people with cancer are not optimal or evidence-based\(^{(11)}\). The need is compelling for a more comprehensive and differentiated understanding of energy and protein requirements in this heterogeneous population. Future research should integrate nutritional goals of energy retention and balance, for the development of guidelines and recommendations targeting individuals with different physiological needs to prevent or delay sarcopenia, and improve muscle mass while also optimising fat mass.

**Acknowledgement**

We thank Dr Vickie Baracos for kindly providing the data for the development of Figs. 4 and 7.

**Financial Support**

None.

**Conflicts of Interest**

None.

**Authorship**

C. M. P. was responsible for conception and draft of this review (presented at The Nutrition Society Irish Section Meeting, June, 2015); S. J. C., C. E. O. and R. M. O. are collaborators who contributed towards literature review and summary, the development of figures and online supplementary material, also providing scientific input in all content hereby presented. All authors reviewed and approved the manuscript prior to submission.

**References**


41. Prado CMM, Mourtzakis M, Baracos V et al. (2010) Overweight and obese patients with solid tumors may...


